Aptahem AB (publ) (NGM:APTA)

Market Cap	14.01M +73.5%
Revenue (ttm)	2.59M -32.7%
Net Income	-6.49M
EPS	-0.31
Shares Out	20.97M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	53,056
Average Volume	42,042
Open	0.6800
Previous Close	0.6820
Day's Range	0.6380 - 0.8300
52-Week Range	0.5000 - 2.4000
Beta	0.45
RSI	44.54
Earnings Date	May 15, 2026

About Aptahem AB

Aptahem AB (publ), a biotechnology company, engages in the development of ribonucleic acid-based pharmaceuticals in Sweden. The company’s lead product candidate is Apta-1, which is in Phase I clinical trial for the treatment of patients with sepsis/septic shock and severe inflammatory conditions, as well as to prevent organ and tissue damages in life-threatening conditions. It also develops Apta-2 which is in preclinical stage for the treatment of inflammation; and Apta-3 which is in discovery stage. The company has a collaboration with Hongene...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 3
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: APTA

Financial Performance

In 2025, Aptahem AB's revenue was 2.59 million, a decrease of -32.73% compared to the previous year's 3.84 million. Losses were -6.49 million, -24.58% less than in 2024.